← Back to Screener
Microbot Medical, Inc. Common Stock (MBOT)
Price$1.98
Value ScoreC
Growth ScoreF
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)1.41%
Price vs S&P 500 (4W)-8.31%
VGM Score36.42
Market Capitalization$136.34M
All Metrics
Book Value / Share (Quarterly)$1.10
P/TBV (Annual)11.71x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-6.10%
Cash Flow / Share (Quarterly)$-0.23
Price vs S&P 500 (YTD)-9.43%
Gross Margin (TTM)1.90%
Net Profit Margin (TTM)-3496.19%
EPS (TTM)$-0.28
10-Day Avg Trading Volume2.13M
EPS Excl Extra (TTM)$-0.28
Revenue Growth (5Y)0.40%
EPS (Annual)$-0.29
ROI (Annual)-16.95%
Gross Margin (Annual)82.79%
Net Profit Margin (5Y Avg)-5624.44%
Cash / Share (Quarterly)$1.08
Revenue Growth QoQ (YoY)-50.00%
ROA (Last FY)-16.12%
EBITD / Share (TTM)$-0.29
ROE (5Y Avg)-167.81%
Operating Margin (TTM)-4114.29%
Cash Flow / Share (Annual)$-0.20
P/B Ratio1.84x
P/B Ratio (Quarterly)2.18x
Net Income / Employee (Annual)$-305,600
EV / Revenue (TTM)1263.69x
Net Interest Coverage (TTM)-113.63x
ROA (TTM)-20.71%
EV / EBITDA (TTM)5.19x
EPS Incl Extra (Annual)$-0.29
Current Ratio (Annual)23.33x
Quick Ratio (Quarterly)21.73x
3-Month Avg Trading Volume2.04M
52-Week Price Return-24.25%
Revenue / Employee (TTM)$2,400
Tangible BV / Share (Quarterly)$97.43
P/S Ratio (Annual)134.99x
Asset Turnover (Annual)0.03x
52-Week High$4.67
Operating Margin (5Y Avg)-5730.35%
EPS Excl Extra (Annual)$-0.29
CapEx CAGR (5Y)-7.79%
Tangible BV CAGR (5Y)-27.14%
26-Week Price Return17.34%
Quick Ratio (Annual)23.04x
13-Week Price Return-20.70%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)22.59x
Enterprise Value$132.69M
Revenue / Share Growth (5Y)-23.91%
Asset Turnover (TTM)0.00x
Book Value / Share Growth (5Y)-19.51%
Revenue / Employee (Annual)$23,500
Pretax Margin (Annual)-3194.06%
Cash / Share (Annual)$1.17
3-Month Return Std Dev70.12%
Net Income / Employee (TTM)$-330,500
ROE (Last FY)-16.95%
Net Interest Coverage (Annual)-113.00x
EPS Basic Excl Extra (Annual)$-0.29
P/FCF (TTM)5.68x
Receivables Turnover (TTM)27.71x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.28
Receivables Turnover (Annual)7.48x
ROI (TTM)-21.84%
P/S Ratio (TTM)1298.52x
Pretax Margin (5Y Avg)-5540.77%
Revenue / Share (Annual)$25.25
Tangible BV / Share (Annual)$137.75
Price vs S&P 500 (52W)-52.46%
Year-to-Date Return1.50%
5-Day Price Return18.71%
EPS Normalized (Annual)$-0.29
ROA (5Y Avg)-108.07%
Net Profit Margin (Annual)-3241.58%
Month-to-Date Return-2.87%
Cash Flow / Share (TTM)$-1.14
EBITD / Share (Annual)$-0.31
Operating Margin (Annual)-3301.98%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-167.81%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-0.28
P/TBV (Quarterly)6.38x
P/B Ratio (Annual)1.73x
Pretax Margin (TTM)-3496.19%
Book Value / Share (Annual)$1.15
Price vs S&P 500 (13W)-30.45%
Beta1.02x
Revenue / Share (TTM)$0.00
ROE (TTM)-21.84%
52-Week Low$1.60
vGradeC
gGradeF
mGradeC
vgmGradeD
Show chart for
Earnings Surprise History
Q1 26-0.05est. -0.08
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.13
4.11
4.11
4.11
Industry Peers — Surgical & Medical Instruments(138)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
MBOTMicrobot Medical, Inc. Common Stock | C | F | C | $1.98 |
| SYKStryker Corporation | C | C | D | $299.46 |
| MMM3M Company | C | F | C | $150.93 |
| BSXBoston Scientific Corp. | C | B | F | $47.98 |
| MDLNMedline Inc. Class A common stock | C | D | D | $35.75 |
| BDXBecton, Dickinson and Co. | B | C | C | $145.33 |
| DXCMDexCom, Inc. | C | B | C | $74.87 |
| RMDResMed Inc. | B | B | D | $186.44 |
| WSTWest Pharmaceutical Services, Inc. | D | C | B | $316.30 |
| SOLVSolventum Corporation | C | D | C | $75.84 |
| PENPenumbra, Inc. | F | C | C | $318.95 |
About
Microbot Medical develops robotic solutions for endovascular procedures, a minimally invasive approach to treating vascular conditions. The company's LIBERTY Endovascular Robotic System is a single-use, remotely operated platform designed to enhance precision and provider safety in vascular interventions. With a robust intellectual property portfolio, Microbot aims to establish a new standard in endovascular care delivery.